Mylan Reports Adjusted Diluted Cash EPS of $0.11 for t...( On Track to Delive...),Health

On Track to Deliver Targeted Synergies

Sells Rights to Bystolic(TM) (Nebivolol) for $370 Million in Cash

To Consider a Sale of Dey Specialty Business

PITTSBURGH, Feb. 27 /PRNewswire-FirstCall/ -- Mylan Inc. (NYSE: MYL) today announced its financial results for the three and nine months ended December 31, 2007, provided an update on its synergy targets for the Merck Generics acquisition, and announced a number of strategic and operational initiatives.

Financial Highlights

-- Adjusted diluted cash EPS of $0.11 and $0.92 for the three and nine

months ended December 31, 2007, respectively, both of which exclude the

impact of purchase accounting items related to the Matrix acquisition

completed in January 2007 and the acquisition of Merck Generics

completed in October 2007, as well as other non-recurring items as

discussed in detail below;

-- Total revenues of $1.16 billion for the three months ended December 31,

2007, an increase of $753.6 million over the same prior year period;

-- Total revenues of $2.18 billion for the nine months ended December 31,

2007, an increase of $1.05 billion over the same prior year period;

-- On a GAAP basis, a loss per diluted share of $5.04 and $4.49 for the

three and nine months ended December 31, 2007, respectively, as a

result of purchase accounting adjustments including the write-off of

$1.27 billion of acquired in-process research and development, which

was recorded without tax effect.

Robert J. Coury, Mylan's Vice Chairman and CEO, commented: "The strength of this first quarter as a consolidated company showcases Merc
'/>"/>